Matthew Oristano
Chief Executive OfficerMr. Oristano is the President and CEO of Reaction Biology since 2004. He has led strategy and finance of the company and negotiated the acquisition of ProQinase in 2019. In addition to his position at RBC, he serves on the board and is the audit committee chairman of Spōk (Nasdaq: SPOK). From 1993 to 1999, Mr. Oristano was Chairman and CEO of People’s Choice TV Corp, a public wireless communications company, which he founded in 1988 and sold to Sprint in 1999. He has extensive experience in corporate strategy, management, finance, marketing, and regulatory compliance. Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.
Haiching Ma, PhD
Chief Scientific OfficerDr. Ma joined Reaction Biology in 2001 as employee number one. He is the Chief Science Officer, where he developed and implemented the current Reaction Biology technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all Reaction Biology totaling over $12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma is serving as a national Steering Committee Member for the NIH National Cancer Institute's Chemical Biology Consortium. He received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.
Sebastian Dempe, PhD
Chief Executive Officer GermanySebastian Dempe is biologist by training and received his doctorate degree from the German Cancer Research Center/ University of Heidelberg in 2010 where he was exploiting the capacity of parvovirus H1, currently tested in clinical studies, for the virotherapy of cancer using various preclinical research models. Starting his career in Business Development at ProQinase (2011-2014), he was later appointed as Executive Director Business Development of Crown Bioscience, Inc., leading the company’s European Business Development team until June 2019. Sebastian re-joined ProQinase as CEO/ Managing Director on July 01, 2019.
Robert Hartman, MSME
Chief Information OfficerRobert Hartman joined Reaction Biology in 2009. Mr. Hartman developed and implemented the R-Net system, which converts unstructured laboratory documents into actionable data. This system drives automation, manages just-in-time inventory, performs statistical analysis, generates client and management reports, and serves as a job planning tool. Other systems designed and implemented at Reaction Biology by Mr. Hartman include database applications that integrate with client LIMS, software that converts client reports into neutral files or databases, and productivity tools that bi-directionally exchange data with client relationship management tools. Mr. Hartman has held the Director of Software Development role at several firms and has managed the development of several hundred commercial software development projects. Mr. Hartman holds a MS degree in Mechanical Engineering from Drexel University.
Goutham G. Reddy, JD
General CounselMr. Reddy joined Reaction Biology as General Counsel in 2018, having been its corporate counsel since 2013. Prior to that, he was Corporate Counsel at Strategic Diagnostics and Senior Counsel at Cigna. Mr. Reddy oversees all legal affairs of Reaction Biology and its subsidiaries, in addition to assisting in M&A transactions. Mr. Reddy received his Doctor of Law degree from Case Western Reserve University School of Law. He also has a degree in biology from Kent State University.
Kurumi Horiuchi, PhD
Director of Biochemistry, USAKurumi Horiuchi, PhD joined Reaction Biology in 2004. She is responsible for assay development and handles orders for custom biochemical assay development, including kinetic analysis for mechanism of action studies. Previously, she held positions as an enzymologist in the Enzymology Department at DuPont Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb, where she was involved in all stages of drug discovery, from target identification to clinical studies, including HTS, SAR, and mode of action studies for lead compounds. As an enzymologist, she focused specifically on difficult enzymes and problem compounds and developed assays for kinetic analyses in areas including cancer, inflammatory diseases, cardiovascular diseases, and antibacterial and antiviral therapies. Dr. Horiuchi holds a Ph.D. in Biophysics from the School of Science and Engineering at Waseda University. She completed postdoctoral training at the University of Pennsylvania, with a focus on smooth muscle regulation.
Ekaterina Kuznetsova, PhD
Director of Product Development, USAEkaterina Kuznetsova, PhD joined Reaction Biology in 2014, concentrating on developing new assays for epigenetic targets, and leading Reaction Biology’s protein production group. Dr. Kuznetsova has a broad background in enzymatic assay development and has intensive experience in working with epigenetic targets, as well as other enzymatic families. Dr. Kuznetsova’s research is published in a number of peer-reviewed journals, including the Journal of Biological Chemistry, Nature Biotechnology, and ACS Medicinal Chemistry Letters. She received her Ph.D. from the University of Toronto in 2009, focusing on areas of proteomics and biochemistry. She continued her training as a postdoctoral scientist at the Structural Genomics Consortium (MBB/Karolinska Institute, Sweden), working on the evaluation of PARP inhibitors. After that, Dr. Kuznetsova worked at SGC Toronto, University of Toronto as a Research Associate concentrating on epigenetic assay development and HTS for early-stage drug discovery.
Michael Kubbutat, PhD
Head of Biochemical Drug Discovery and Head of Drug Development, GermanyMichael Kubbutat studied biology and cell biology and obtained his Ph.D. at the Research Center Borstel, Germany. In 1994, Michael Kubbutat started post-doctoral studies at the Ludwig Institute for Cancer Research (London, UK) in the group of Prof. Karen Vousden. Together with the group of Prof. Vousden, he moved in 1995 to the National Cancer Institute, Frederick, USA. In 1999 he joined the Tumor Biology Center Freiburg, Germany first as a group leader (Molecular Cell Biology), and later as Head of the Target Identification & Validation Department. In 2001 he joined ProQinase as Head of R&D. Since 2010, Michael Kubbutat is Head of Biochemical Drug Discovery & Head of Drug Development at Reaction Biology Europe.
Holger Weber, PhD
Head of In Vivo Pharmacology, Project Management & Internal InnovationsHolger Weber studied biology and obtained his Ph.D. at the Max-Planck Institute for Immunobiology in Freiburg, Germany. In 2001 he joined the research group of Prof. Augustin at the Tumor Biology Center, Freiburg. The scientific focus and interest during that time was the field of angiogenesis, first as a Post-Doc, later as a group leader. In 2007 he left basic research and started to work at ProQinase as a group leader in the Department of Cellular Drug Discovery. Since 2014, Holger Weber is Head of In Vivo Pharmacology responsible for the resorts Project Management and Internal Innovations.
Project Management & Animal Affairs
Cynthia Obodozie, DVM, PhD
Head of In Vivo PharmacologyProject Management & Animal Affairs
After completing her veterinary studies in Berlin, Germany, Cynthia wrote her doctoral thesis at the pharmaceutical company Bayer (formerly Schering AG, Berlin) in the preclinical oncology department in the field of antiestrogens and their anti-tumor effects on endometrial cancer. As a postdoc, Cynthia worked for 3 years at the KTB Tumorforschungs GmbH in Freiburg, Germany, in the angiogenesis research department with a focus on tumor angiogenesis. Then she switched to ProQinase GmbH and worked as a senior scientist and later as a group leader in the in vivo pharmacology department. In this role, she is involved in the implementation and supervision of in vivo studies as well as customer communication and advice. In the additional position as Head of Animal facility, she takes care of the concerns of the animals, the equipment, and the staff as well as the official regulations regarding animal studies. In her role as Head of in vivo Pharmacology, she manages the department in a dual leadership and thus influences the direction and future goals of the department.
Jan Ehlert, PhD
Head of Cellular Drug Discovery, GermanyJan Erik Ehlert is cell biologist by training and has gained his PhD at the Research Center Borstel, Germany, in the field of chemokine biology in innate immunology. During his Postdoc studies at the University of Michigan in Ann Arbor, he extended his scientific focus on the relevance of angiogenesis in lung cancer. In the year 2001, Jan Ehlert joined ProQinase as group leader in the field of target identification and validation in cancer biology. Since 2010, he is member of the management team at ProQinase as Head of the Department of Cellular Drug Discovery. His team is specialized on cellular assay systems in oncology, cellular screening and 3D assay systems. Jan Ehlert is co-inventor in several patents on compound classes issued to treat kinase-related cancer diseases.
Bob Dougherty, PhD
Director of In Vitro Pharmacology, USARobert Dougherty, PhD joined Reaction Biology in 2018, bringing 30 years of pharmacology experience with an emphasis on cell-based drug discovery. Dr. Dougherty was previously Director of Discovery Biology for Jubilant Biosystems ion-channel group before it was acquired by Reaction Biology. Prior to that, he was the Director of Cellular Pharmacology for Amphora Discovery. He holds a Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University School of Medicine.
Yangbo Feng, PhD
Director of Medicinal Chemistry and Director of Drug Discovery and Development, USAYangbo Feng Ph.D. joined RBC in 2016. He provides medicinal chemistry advisory services to Reaction Biology customers. Dr. Feng has been the principal investigator on multiple research grants. Prior to joining Reaction Biology, Dr. Feng was Associate Director of Medicinal Chemistry at The Scripps Research Institute. He holds a Ph.D. in organic chemistry from UC San Diego.
Rebecca Eells, PhD
Associate Director of BiophysicsRebecca Eels, PhD joined RBC in 2018 and is the head of the biophysical assay services. Her group has developed and performed SPR projects for customers covering a large number of drug targets, involving broad range therapeutic areas, including cancer, antiviruses, etc. Dr. Eels has a broad background in biophysical assay development, specializing in SPR. She holds a Ph.D. in Molecular Biophysics and Structural Biology from Carnegie Mellon University.
Jianghong Wu, PhD
Associate Director Of Cell BiologyJianghong Wu, PhD joined RBC in 2012 and leads a team that performs kinase cell-based target engagement assays and other cell-based customer services. Dr. Wu has extensive experience in cell biology, molecular biology, and drug screening studies, and has over 20 years of research experience. He holds a Ph.D. degree in immunology from Nagoya University, Japan and did postdoctoral studies at the University of Toronto, and Thomas Jefferson University.
Claudia D. Pérez Ortega, PhD
Associate Director of Kinase ServicesClaudia D. Pérez Ortega, PhD joined Reaction Biology in 2019 and oversees a team of project managers to lead and perform kinase customer service. Dr. Pérez Ortega has a strong background in Biochemistry, Enzymology, Molecular, and Cell biology and proven lab work experience. She joined Reaction Biology from DuPont Pioneer, and holds a Ph.D. degree in Biochemical Sciences from the Biotechnology Institute of Universidad Nacional Autónoma de México (UNAM) and did postdoc training at Universidad Nacional Autónoma in Madrid.
Earl Gordon, PhD
Manager, Ion Channel ServicesEarl Gordon joined Reaction Biology in 2018. He oversees the company’s ion channel assay facility with both automated and manual patch clamp services. Prior to joining Reaction Biology, Dr. Gordon was Senior Scientist with Jubilant Discovery Services, assisting customers with pre-IND ion channel assays, and before that led the electrophysiology group at Knopp Biosciences as they advanced their Kv7 ion channel modulator for epilepsy. Dr. Gordon received a Ph.D. in Pharmacology from Cornell University.
Kayleigh McGovern-Gooch, PhD
Manager of the Non-Kinase Biochemical Group, USAKayleigh McGovern-Gooch, PhD joined Reaction Biology in 2019, and manages all non-kinase assay activity, including a large number of fluorescent format assay groups such as HDAC, Protease, Deubiquitinase, Phosphatase, etc. She completed her graduate work at Syracuse University, where she developed novel activity assays and discovered small molecule inhibitors for ghrelin O-acyltransferase.
小汤姆·佩青格（Tom Petzinger）
Petzinger先生是生物技术开发公司LaunchCyte的首席执行官。 Petzinger先生还担任Immunetrics Inc.，Crystalplex Corp，Proteopure Inc.和Knopp Neurosciences的董事长。 在共同创立LaunchCyte之前，他在《华尔街日报》度过了22年的时光，在那里他曾担任华盛顿经济编辑，华盛顿分社副社长，千年编辑和每周专栏作家。 他是普利策（Pulitzer）提名人，曾多次参与调查，还撰写了三本最畅销的商业书籍。 他获得西北大学的新闻学博士学位，并在那里成为Richter国际学者。
Matthew Oristano
Oristano先生自2004年以来一直担任React Biology的总裁兼首席执行官。他领导公司的战略和财务工作，并于2019年就收购ProQinase进行了谈判。除他在RBC的职务外，他还担任董事会成员并担任审计委员会 Spōk（纳斯达克股票代码：SPOK）董事长。 从1993年到1999年，Oristano先生担任公共无线通信公司People's Choice TV Corp的董事长兼首席执行官，该公司于1988年成立，并于1999年出售给Sprint。他在公司战略，管理，财务，市场营销， 和法规遵从性。 Oristano先生拥有Rennselaer理工学院的物理学学位。
Michael Kramer
克雷默（Kramer）先生常驻纽约，在为全球公司和政府就总计数千亿美元的金融交易提供咨询方面有着丰富的经验。 他目前是Ducera Partners LLC的创始合伙人。 在此之前，他一直是Perella Weinberg Partners的高级合伙人，Greenhill＆Co管理委员会成员，Houlihan Lokey Howard＆Zukin公司的并购和财务重组负责人。
Haiching Ma, PhD
马博士于2001年加入反应生物学，成为第一名员工。 他是首席科学官，在那里他开发和实施了当前的反应生物学技术和服务平台。 马博士是多个SBIR奖的首席研究员，并获得了美国国立卫生研究院所有反应生物学的RO1奖，总额超过1200万美元，涉及的研究主题包括人体kinome和表观基因组靶标的测定开发，毒性预测，化学微阵列HTS和细胞死亡预防 减少放射疗法的副作用。 马博士是美国国立卫生研究院国家癌症研究所化学生物学协会的全国指导委员会委员。 他获得了博士学位。 在宾夕法尼亚大学医学院获得药理学博士学位，并在那里继续在医学和工程学院进行博士后培训。
Jonathan Kaufman, PhD
Kaufman博士是Lipella Pharmaceuticals，Inc.的首席执行官。在共同创立Lipella之前，Kaufman博士曾是生物技术公司孵化器LaunchCyte LLC的副总裁兼首席科学官。 在LaunchCyte，Kaufman博士是Proteopure Inc.和Knopp Neuroscience Inc.的联合创始人。 担任Crystalplex Corp.的创始总裁。 在反应生物学公司，Crystalplex公司和Immunetrics公司的董事会任职； 在加入LaunchCyte之前，考夫曼博士曾在默克公司化学制造部门的新技术委员会任职，并在生物信息学部门担任葛兰素史克的顾问。 Kaufman博士拥有沃顿商学院金融学的MBA学位，并拥有宾夕法尼亚大学医学院的生物物理学博士学位。